Emerging vaccine nanotechnology: From defense against infection to sniping cancer

Chan Feng; Yongjiang Li; Bijan Emiliano Ferdows; Dylan Neal Patel; Jiang Ouyang; Zhongmin Tang; Na Kong; Enguo Chen; Wei Tao

Acta Pharmaceutica Sinica B (May 2022)

Emerging vaccine nanotechnology: From defense against infection to sniping cancer

Chan Feng,
Yongjiang Li,
Bijan Emiliano Ferdows,
Dylan Neal Patel,
Jiang Ouyang,
Zhongmin Tang,
Na Kong,
Enguo Chen,
Wei Tao

Affiliations

Chan Feng: Department of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China; Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Cancer Center, Zhejiang University, Hangzhou 310058, China
Yongjiang Li: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Pharmacy, the Second Xiangya Hospital of Central South University, Changsha 410011, China
Bijan Emiliano Ferdows: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Dylan Neal Patel: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Jiang Ouyang: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Zhongmin Tang: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Na Kong: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Enguo Chen: Department of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China; Cancer Center, Zhejiang University, Hangzhou 310058, China; Corresponding authors. Fax: +001 857 307 2337 (Wei Tao).
Wei Tao: Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Corresponding authors. Fax: +001 857 307 2337 (Wei Tao).

Journal volume & issue: Vol. 12, no. 5
pp. 2206 – 2223

Abstract

Read online

Looking retrospectively at the development of humanity, vaccination is an unprecedented medical landmark that saves lives by harnessing the human immune system. During the ongoing coronavirus disease 2019 (COVID-19) pandemic, vaccination is still the most effective defense modality. The successful clinical application of the lipid nanoparticle-based Pfizer/BioNTech and Moderna mRNA COVID-19 vaccines highlights promising future of nanotechnology in vaccine development. Compared with conventional vaccines, nanovaccines are supposed to have advantages in lymph node accumulation, antigen assembly, and antigen presentation; they also have, unique pathogen biomimicry properties because of well-organized combination of multiple immune factors. Beyond infectious diseases, vaccine nanotechnology also exhibits considerable potential for cancer treatment. The ultimate goal of cancer vaccines is to fully mobilize the potency of the immune system as a living therapeutic to recognize tumor antigens and eliminate tumor cells, and nanotechnologies have the requisite properties to realize this goal. In this review, we summarize the recent advances in vaccine nanotechnology from infectious disease prevention to cancer immunotherapy and highlight the different types of materials, mechanisms, administration methods, as well as future perspectives.

Published in Acta Pharmaceutica Sinica B

ISSN: 2211-3835 (Print); 2211-3843 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://www.journals.elsevier.com/acta-pharmaceutica-sinica-b

About the journal

Abstract

Keywords